Briefly, an initiating genetic mutation, such as the IDH1/2 mutation, is an overture to the complex and dynamic interplay between metabolic, epigenetic, and genetic alterations, leading to a global dysregulation of gene expression (linked to cell cycle regulation, DNA repair mechanisms, apoptosis, cell differentiation, metabolic pathways, and redox homeostasis) and consequently gliomagenesis and metastasis with characteristic malignant GBM heterogeneity, plasticity, vascularity, invasiveness, and aggressiveness [10,11,12,13]. This evidence concerns the gene IDH1 and glioblastoma.